{"id":"0fb4f355-60bb-4d39-b49d-e1f32024b088","arxiv_id":"2508.16424","paper_version":1,"verdict":"UNVERDICTED","confidence":"LOW","novelty_score":5.0,"correctness_risk":"unknown","formal_verification":"none","parameter_count":1,"one_line_summary":"CAMP, a two-stage convolutional autoencoder and CNN with adaptive sparse penalties, reportedly predicts MGMT methylation status from MRI with 0.97 accuracy.","lead":"This paper proposes a deep learning framework called CAMP that predicts MGMT gene methylation status in glioblastoma patients from MRI scans, claiming near-perfect accuracy. If the result holds, it could help doctors choose temozolomide treatment without invasive biopsy.","discovery_kind":"extension","skeptic_critique":{"model":"deepseek-v4-flash","headline":"Central 0.97 accuracy claim is unverifiable: the submitted full text is corrupt and contains unrelated x-ray astronomy content, so no methodology, data, or evaluation details can be audited; the synthetic-data step additionally raises a concrete leakage risk.","rationale":"The reader's verdict of UNVERDICTED is appropriate. The central claim cannot be checked because the full text is unreadable and interleaved with unrelated content; this is a missing-support problem, not a disagreement with consensus. I partially agree with the reader's weakest assumption: synthetic-data leakage is a plausible mechanism for inflating accuracy, and it is the only content-based risk visible in the abstract. However, the more fundamental blocker is that no method or results are available, so even the existence of the CAMP framework cannot be confirmed from the submission. The proposed concrete test—recovering a clean source and checking the data split and augmentation protocol—would settle whether the leakage concern is real and whether the reported numbers are reproducible. No independent evidence (code, formal verification, or public benchmarks) is present to offset this. Therefore the correct disposition remains unverdictable pending the availability of an intact manuscript.","tokens_in":19634,"tokens_out":3749,"duration_ms":48449,"concrete_test":"Obtain the original LaTeX/PDF source of arXiv:2508.16424 from arXiv and compile it; if a clean version is recoverable, inspect the dataset and experimental sections to verify: (1) cohort size and MGMT label acquisition, (2) patient-level train/test split, and (3) that the autoencoder was trained only on training-set patients and synthetic slices were generated only for training-set patients. Then rerun the reported classifier under that split with and without synthetic augmentation. If the clean source is unobtainable or the described split allows any patient overlap, the 0.97 accuracy must be re-evaluated; an independent benchmark, e.g., BraTS-MGMT with a standard 2D CNN, should be used as a sanity check.","verdict_should_be":"UNCHANGED","load_bearing_attack":"The abstract's strong claim—CAMP achieves accuracy 0.97, specificity 0.98, sensitivity 0.97 on benchmark datasets—requires that a real model was trained and evaluated on accessible data with an honest split. Nothing in the supplied full text supports this. The text is almost entirely mangled, and many pages are from an unrelated X-ray astronomy paper (MAXI, NICER, IXPE, NuSTAR light curves and spectra). There is no readable Methods section, no dataset table, no patient counts, no MRI modality details, no hyperparameter settings, no cross-validation description, and no code or reproducibility statement. The central claim therefore has zero verifiable support. A secondary but specific mechanism that could explain an inflated 0.97 is label leakage through the two-phase autoencoder: if synthetic MRI slices are generated from patients who also appear in the test set, or if the autoencoder is trained with access to MGMT methylation labels, the downstream CNN can learn shortcut features that do not generalize. The abstract explicitly says the autoencoder 'captures and preserves' tumor structures, but it does not state whether generation is conditioned on the label or whether subjects are disjoint. Both the absence of readable evidence and this leakage possibility prevent acceptance of the claim.","agreement_with_reader":"partial"},"referee_report":{"model":"deepseek-v4-flash","summary":"The manuscript proposes CAMP (Convolutional Autoencoders for MGMT Methylation Status Prediction), a two-phase deep-learning framework for predicting MGMT promoter methylation in glioblastoma from MRI. Phase 1 uses a tailored autoencoder with adaptive sparse penalties to generate synthetic MRI slices; Phase 2 uses a CNN with adaptive sparse penalties to classify methylation status. The abstract reports accuracy 0.97, specificity 0.98, and sensitivity 0.97 on benchmark datasets, and claims significant improvement over existing methods. The submitted full text, however, is largely unreadable: most of it is mojibake, and long stretches contain an unrelated X-ray astronomy paper (MAXI, NICER, IXPE, NuSTAR light curves, phase-resolved spectroscopy, and polarization fits). No readable methods, dataset description, evaluation protocol, equations, or code are present. The headline performance therefore has no verifiable support in the submission.","tokens_in":19963,"tokens_out":4963,"duration_ms":53121,"significance":"If the reported 0.97/0.98/0.97 metrics were robust, this would be a clinically significant contribution: non-invasive prediction of MGMT status from routine MRI could help guide temozolomide decisions and reduce dependence on biopsy. The idea of using a sparse-penalized autoencoder to synthesize training slices is also a plausible augmentation direction, and the paper states its headline metrics explicitly. However, the manuscript as submitted ships no machine-checked proofs, no reproducible code, no dataset description, and no readable evaluation protocol. The only evidence for the headline claim is the abstract sentence. The paper's strength is therefore limited to a concrete set of reported numbers and a plausible hypothesis; the submission does not currently provide grounds to believe those numbers.","major_comments":[{"comment":"The central claim—accuracy 0.97, specificity 0.98, sensitivity 0.97—is supported only by the abstract. The submitted full text is not a coherent manuscript: it consists of unreadable mojibake and, from the first figure onward, contains large passages from an unrelated X-ray astronomy paper (figure labeled 'MAXI Flux [cts/s/cm2] (2–20 keV)', NICER/IXPE/NuSTAR light curves, phase-resolved spectroscopy, and polarization fits). There is no readable Methods section, dataset description, or evaluation protocol. A performance claim that cannot be traced to a described experiment is not auditable.","section":"Abstract (central claim) vs. Full text (all pages)"},{"comment":"Even taking the abstract at face value, the evaluation protocol is underspecified. The submission provides no patient or subject counts, no MRI modality list (T1, T1c, T2, FLAIR?), no definition of the 'benchmark datasets', no train/test split or cross-validation scheme, no hyperparameter settings, no class-balance information, and no code or reproducibility statement. Without these, the reported metrics are uninterpretable and the claim of 'significantly outperforming existing methods' cannot be checked.","section":"Abstract, second paragraph (CAMP two-phase pipeline)"},{"comment":"The synthetic-slice step poses a concrete leakage risk that the manuscript does not rule out. If the autoencoder is trained on patients who also appear in the test split, or if generation is conditioned on or trained with MGMT methylation labels, the downstream CNN can learn patient-identifying or label-derived shortcuts rather than methylation-correlated tissue structure. The abstract states that the autoencoder 'captures and preserves' tumor structures but does not state whether synthetic samples are subject-disjoint from test patients or whether the autoencoder has any access to methylation labels. This ambiguity is load-bearing because it could explain the near-perfect 0.97 accuracy.","section":"Abstract, second paragraph (synthetic MRI generation)"},{"comment":"The paper's stated novelty is the 'adaptive sparse penalty', but the submitted text contains no parseable mathematical definition of it. The unreadable fragments near '����������' and '������' do not constitute an equation, and no formal loss function or optimization objective is given in readable form. Since the contribution is claimed to be the method, the absence of the method's definition is a load-bearing gap, not merely a presentation issue.","section":"Full text, equation-like fragments (pp. 9–10)"}],"minor_comments":[{"comment":"The phrase 'significantly outperforming existing methods' is not accompanied by any readable comparison table, baseline list, or statistical test in the submitted text. A resubmission must make the comparison explicit.","section":"Abstract vs. full text"},{"comment":"No readable references section is present. Prior work on MGMT methylation prediction from MRI is not cited, making it impossible to position the claimed improvement in the literature.","section":"Full text, references"},{"comment":"The encoding of the full text is severely corrupted; even section headings are unreadable. The unrelated X-ray astronomy content should be removed if this is a compilation error. The manuscript is not reviewable in its current form.","section":"Full text, PDF integrity"}],"recommendation":"reject","confidential_remarks":"This submission appears to be a corrupted or misassembled PDF, with content from a separate X-ray astronomy paper interleaved. The editor may wish to check with the authors before further processing; the submitted file is not a valid manuscript. The astronomy content suggests a source-file/PDF pipeline error rather than a substantive methods claim, but the paper as submitted cannot be evaluated. A future resubmission with a clean, complete manuscript would be needed."},"author_rebuttal":null,"desk_editor":{"model":"deepseek-v4-flash","letter":"Hi [Name],\n\nQuick take: this is not a paper you can referee. The abstract describes a plausible pipeline — autoencoder-based synthetic MRI augmentation plus a CNN with adaptive sparse penalties — for MGMT methylation prediction, and it reports 0.97 accuracy. But the full text is a mangled mess, with large sections of text from an unrelated X-ray astronomy paper (MAXI/NICER/IXPE/NuSTAR). There is no readable methods section, no dataset table, no patient counts, no MRI protocol, no cross-validation scheme, and no code. The central claim has literally zero verifiable support.\n\nWhat the paper does well, such as it is, is frame the clinical problem clearly: MGMT methylation is a real biomarker for temozolomide response, and a non-invasive imaging surrogate would be genuinely useful. The two-phase architecture is a reasonable-sounding idea, and calling the penalty 'adaptive sparse' at least flags a plausible tweak. None of that counts as a contribution without evidence, but it's not pure noise.\n\nThe soft spots are load-bearing. The 0.97 accuracy is not credible as reported. The synthetic-data step introduces a concrete leakage mechanism: if the autoencoder is trained on patients who also appear in the test set, or if generation is conditioned on the methylation label, the downstream CNN can learn shortcuts that don't generalize. The abstract doesn't say whether subjects were disjoint or whether synthesis was label-conditional. On top of that, the performance is well above what the field typically sees (AUCs in the 0.8–0.9 range), so the burden of proof is even higher.\n\nThere's nothing else to say. This is not a desk-reject-and-forget situation; it's a 'send it back and let them resubmit a clean version' situation. If they come back with real methods and data, the topic and architecture would deserve serious referee time. As it stands, there is nothing to verify.\n\nMy recommendation: desk reject with an invitation to resubmit after fixing the text and adding the missing evidence.\n\nBest,\n[You]","headline":"An abstract with a 0.97 accuracy claim and a corrupted body — not reviewable until replaced with a real manuscript.","tokens_in":20382,"tokens_out":2423,"would_cite":false,"duration_ms":25246,"reading_group":"no","serious_thinker":"unclear","would_accept_peer_review":false},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"deepseek-v4-flash","headline":"The paper claims a two-stage convolutional-autoencoder framework, CAMP, predicts MGMT methylation status from MRI with 0.97 accuracy, 0.98 specificity, and 0.97 sensitivity on benchmark datasets.","keywords":["MGMT methylation","glioblastoma","MRI","convolutional autoencoder","adaptive sparse penalty","synthetic image generation","temozolomide response prediction","non-invasive biomarker"],"falsifier":"One decisive check: retrain the same classifier on the original real scans alone with patient-level splits and compare accuracy; if it matches 0.97, the synthetic slice stage is not doing the work. A second check: if a classifier can distinguish real from synthetic slices with high accuracy, or if accuracy drops sharply when training and test scans come from different hospitals or scanners, the learned signal is likely an artifact of the augmentation rather than MGMT biology.","tokens_in":19595,"feed_emoji":"🧠","tokens_out":6148,"duration_ms":69083,"temperature":0.7,"pith_summary":"Glioblastoma patients whose tumors carry a methylated MGMT gene respond far better to temozolomide, but today that information usually comes from tissue obtained by biopsy or surgery. This paper tries to make the call non-invasively from MRI, introducing CAMP, a two-phase framework: a tailored autoencoder first generates synthetic MRI slices that preserve tissue and tumor structure across modalities, and a convolutional neural network with adaptive sparse penalties then classifies MGMT methylation status. On benchmark datasets the authors report accuracy 0.97, specificity 0.98, and sensitivity 0.97, above existing methods. If that holds, CAMP would give clinicians a fast, imaging-only way to identify patients likely to benefit from temozolomide and to monitor changes during treatment.","feed_headline":"MRI reads a brain tumor's chemo sensitivity with 97% accuracy","feed_subtitle":"A two-stage model synthesizes MRI slices, then flags the MGMT gene switch that decides whether temozolomide will work.","key_machinery":"The load-bearing object is the CAMP framework, a two-phase convolutional autoencoder plus CNN. The named mechanism inside it is the adaptive sparse penalty applied to the CNN: rather than one fixed regularization strength for all images, the penalty adjusts per sample based on data variation such as contrast and tumor location. In phase one the autoencoder's job is not just denoising but generating new MRI slices that preserve the structures believed to correlate with methylation; those synthetic slices supply the classifier with more examples. The whole argument depends on this generated data carrying the same biological signal as real scans.","core_discovery":"The central claim is that MGMT methylation status—a DNA modification that silences a DNA-repair gene and makes glioblastoma cells more vulnerable to alkylating chemotherapy—can be read from routine MRI by a learning pipeline. The pipeline, named CAMP, works in two stages. Stage one trains a convolutional autoencoder to synthesize MRI slices that keep the brain's tissue, fat, and tumor structures intact across MRI modalities, expanding the training data. Stage two trains a CNN whose training includes an adaptive sparse penalty that changes per sample, letting the classifier adjust to contrast differences and tumor-location variability. The authors report that on benchmark datasets CAMP achiev","pith_inferences":["The supplied full text is for the most part not readable as the described methods/results section, so the 0.97 claim can only be checked at the abstract level; a complete version with architecture, dataset, and split details would be needed to verify it.","The 0.97 numbers come from benchmark datasets; if slices of the same patient appear in both training and test sets, the true accuracy for new patients would be lower than reported.","A minimal control experiment is missing: the same CNN trained only on real MRI slices. Without that comparison, it is unclear how much of the gain comes from synthetic augmentation versus the network architecture or the adaptive penalty.","A same design is a natural candidate for other molecular markers in glioblastoma, such as IDH mutation or 1p/19q codeletion, where MRI-based non-invasive prediction is also clinically important."],"forward_implications":["If CAMP's reported accuracy transfers to clinical cohorts, MGMT status could be obtained from standard MRI sequences without biopsy, avoiding surgical risk for patients who cannot undergo tissue sampling.","Patients could be re-scanned over time to watch whether the effective methylation signal changes, which might help decide when to continue or stop temozolomide.","Synthetic slice generation plus adaptive penalties is a recipe for other scarce-data imaging problems where the label is molecular rather than visible in any single image.","The reported specificity of 0.98 means that among the benchmark's unmethylated cases almost all were correctly identified, which matters because falsely treating a non-responder as a responder would expose the patient to an ineffective drug's side effects."],"supporting_citations":[],"fun_headline_variants":["MRI predicts chemo sensitivity in glioblastoma with 97% accuracy","Two-stage AI decodes MGMT methylation from MRI scans","CAMP framework maps MRI to MGMT status for precision glioblastoma therapy","Autoencoder-CNN pipeline reads MGMT methylation from MRI","97% accurate: AI model flags MGMT methylation in brain tumors"],"cache_read_input_tokens":2688,"weakest_assumption_plain":"The result stands on the autoencoder's synthetic MRI slices preserving the same tissue and tumor structures that actually carry MGMT methylation information, and on those slices adding no label leakage or distribution shift; if the generated images encode class artifacts or look different from real scans, the reported accuracy is inflated.","fun_headline_variants_meta":{"raw":{"variants":["MRI predicts chemo sensitivity in glioblastoma with 97% accuracy","Two-stage AI decodes MGMT methylation from MRI scans","CAMP framework maps MRI to MGMT status for precision glioblastoma therapy","Autoencoder-CNN pipeline reads MGMT methylation from MRI","97% accurate: AI model flags MGMT methylation in brain tumors"]},"model":"deepseek-v4-flash","effort":"low","cost_usd":0.000185,"raw_usage":{"total_tokens":1196,"prompt_tokens":817,"completion_tokens":379,"prompt_tokens_details":{"cached_tokens":256},"prompt_cache_hit_tokens":256,"prompt_cache_miss_tokens":561,"completion_tokens_details":{"reasoning_tokens":306}},"tokens_in":561,"tokens_out":379,"duration_ms":4551,"temperature":1.0,"reasoning_tokens":306,"cache_read_input_tokens":256,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-08-05T17:18:02.327404+00:00","model_set":{"reader":"deepseek-v4-flash"},"falsifier":"One decisive check: retrain the same classifier on the original real scans alone with patient-level splits and compare accuracy; if it matches 0.97, the synthetic slice stage is not doing the work. A second check: if a classifier can distinguish real from synthetic slices with high accuracy, or if accuracy drops sharply when training and test scans come from different hospitals or scanners, the learned signal is likely an artifact of the augmentation rather than MGMT biology.","supporting_citations":[],"review_version":1}